MedTrace Logo

Effect of Weight and/or Obesity on Dapsone Drug Concentrations

NCT01165840 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 37

Last updated 2016-07-21

Study results available
· View outcomes & findings →

Summary

This study will find how weight affects the dosing of a drug called dapsone. Currently, the amount of dapsone a patient receives is the same regardless of the patient's weight.

Conditions

Interventions

DRUG

Dapsone

100 mg PO x 1 dose

Sponsors & Collaborators

  • National Center for Research Resources (NCRR)

    collaborator NIH

  • Texas Tech University Health Sciences Center

    lead OTHER

Principal Investigators

  • Ronald Hall, PharmD, MSCS · Texas Tech UHSC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2012-05-31
Completion
2012-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01165840 on ClinicalTrials.gov